Alnylam Pharmaceuticals
ALNY
#577
Rank
NZ$56.68 B
Marketcap
$441.51
Share price
-0.48%
Change (1 day)
45.56%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of June 2024 : NZ$2.10 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is NZ$2.10 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31NZ$2.06 B-0.73%
2022-12-31NZ$2.07 B42.75%
2021-12-31NZ$1.45 B101.01%
2020-12-31NZ$0.72 B60.9%
2019-12-31NZ$0.45 B907.51%
2018-12-31NZ$44.7 M5.83%
2017-12-31NZ$42.24 M-80.49%
2016-12-31NZ$0.21 B
2007-12-31NZ$8.74 M-32.56%
2006-12-31NZ$12.96 M19.86%
2005-12-31NZ$10.81 M7.21%
2004-12-31NZ$10.09 M252.89%
2003-12-31NZ$2.85 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
NZ$0.19 B-90.94%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$4.37 B 107.38%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$2.21 B 5.08%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.43 B-79.33%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.09 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$46.85 B 2,123.44%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$41.15 B 1,852.96%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$30.58 B 1,351.41%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel